Impact of renal function on edoxaban antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease: a prespecified analysis of the EPIC-CAD trial

EuroIntervention 2026 Open access

Read full text
Authors: Joong Min Lee, Min Soo Cho, Do-Yoon Kang, Jung-Min Ahn, Yong-Seog Oh, Chang Hoon Lee, Eue-Keun Choi, Ji Hwan Lee, Chang Hee Kwon, Gyung-Min Park, Hyung Oh Choi, Kyoung-Ha Park
+12 more Kyoung-Min Park, Jongmin Hwang, Ki‐Dong Yoo, Young-Rak Cho, Ji Yeon Kim, Ki Won Hwang, Eun‐Sun Jin, Osung Kwon, Ki-Hun Kim, Seung-Jung Park, Gi-Byoung Nam, Duk-Woo Park
DOI: 10.4244/eij-d-25-01274
Cited by: 1
References: 28

Abstract

BACKGROUND: Renal function is a critical factor of ischaemic and bleeding risks in patients with atrial fibrillation (AF) receiving antithrombotic therapy. AIMS: This study aimed to evaluate the impact of renal dysfunction in patients with AF and stable coronary artery disease (CAD) undergoing antithrombotic therapy. METHODS: The Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease (EPIC-CAD) trial randomised patients to edoxaban monotherapy or dual antithrombotic therapy (edoxaban plus a single antiplatelet agent). In this prespecified analysis, patients were stratified by creatinine clearance into low (

Fields of Study & Subjects

Atrial Fibrillation Management and Outcomes Antiplatelet Therapy and Cardiovascular Diseases Heart Failure Treatment and Management

Publication details

Journal / source
EuroIntervention
Publisher
Europa Digital & Publishing
Volume
22
Issue
8
Pages
e432–e443
Publication date
1 April 2026
Language
EN